No Data
InnoCare Pharma's B-cell Lymphoma-2 Phase III Clinical Trial Approved by NDMA
Express News | InnoCare Pharma - Approval of Registrational Phase III Study of Bcl2 Inhibitor Icp-248 (Mesutoclax) in Combination With Orelabrutinib by Nmpa
INNOCARE (688428.SH): The regulatory Phase III clinical trial of BCL2 inhibitor ICP-248 (Mesutoclax) combined with Obinutuzumab for first-line treatment of CLL/SLL has been approved by the CDE.
On February 17, Great Wisdom announced that INNOCARE (688428.SH) recently learned that its self-developed BCL2 inhibitor ICP-248 (Mesutoclax) in combination with the BTK inhibitor Obatoclax for first-line treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (referred to as "CLL/SLL") has been approved by the National Medical Products Administration (NMPA) Drug Evaluation Center (CDE) to conduct a registration-based Phase III clinical trial. The company has now initiated this clinical research.
Express News | Hong Kong indexes extend gains on Friday, auto makers rise on broad integration of DeepSeek. Biopharma shares soar.
Goldman Sachs released a deep investment value report on China's Biomedical sector, highlighting a bullish outlook on ZAI LAB (ZLAB.US/9688.HK) and four other companies.
Recently, Goldman Sachs released an in-depth investment value analysis report on China's biotechnology. Goldman Sachs believes that it remains Bullish on the biotechnology sector within China's Medical and Healthcare market, as China's innovation is gaining and will continue to gain Global recognition. A number of leading biotechnology companies are expected to achieve breakeven in 2025/2026. This profitability inflection point is of milestone significance for China's biotechnology industry. Goldman Sachs also stated that ZAI LAB (ZLAB.US/9688.HK), Legend Biotech, INNOCARE, BEIGENE, and INNOVENT BIO are preferred symbols, as these companies have all experienced core catalytic events this year.
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
